Health insurance; creating the Ensuring Transparency in Prescription Drugs Prior Authorization Act; determination; consultation; prior authorization; effective date.
HB1808 creates the “Ensuring Transparency in Prescription Drugs Prior Authorization Act” and regulates how health insurers, pharmacy benefits managers (PBMs), and other utilization review entities handle prior authorization for prescription drugs. The bill requires plans to post prior authorization requirements, clinical criteria, and formularies online in clear language, and to notify affected providers and certain enrollees at least 60 days before new or amended restrictions take effect. It also requires adverse determinations and appeals to be reviewed by appropriately licensed professionals, with appeal reviewers generally having the same or similar specialty and no direct involvement or financial interest in the original denial.
The bill sets specific time frames for decisions: urgent prescription drug requests must be decided within 24 hours after all necessary information is received, and nonurgent requests within four business days. If a plan misses those deadlines after receiving information through its authorized system, the drug is deemed authorized. The bill also bars prior authorization for prescription drugs used in emergency health care services, extends prior authorizations for chronic conditions for up to three years in most cases, and requires plans to honor prior authorizations from a previous carrier or product for the first 60 days of new coverage. It excludes certain drugs from the three-year rule, including opioids, other controlled substances, and weight-loss drugs, and it applies to the Oklahoma Medicaid State Plan where allowed by law.
In state-law terms, the bill adds multiple new sections to Title 36 governing health benefit plans, PBMs, and utilization review entities, while also giving enforcement authority to the Insurance Commissioner and the Attorney General. Violations can result in penalties of up to $5,000 per violation, subject to notice and hearing procedures under the Administrative Procedures Act. The act is scheduled to take effect November 1, 2025.
The overall sentiment appears strongly favorable and bipartisan. The bill advanced through House and Senate committees with unanimous or near-unanimous votes, and it passed both chambers by wide margins. That voting pattern suggests broad agreement that prior authorization processes for prescription drugs should be more transparent, timely, and consistent for patients and providers.
The main points of contention are not reflected in committee transcripts, but the structure of the bill indicates likely concerns around administrative burden, insurer and PBM discretion, and the cost or utilization effects of limiting prior authorization. The carve-outs for opioids, controlled substances, and weight-loss drugs, along with the Medicaid-state-plan caveats, suggest lawmakers were balancing access and continuity of care against safety, fraud, and program-compliance concerns.
HB1808 amends Oklahoma insurance law by creating new requirements for prescription drug prior authorization under Title 36, including disclosure, review standards, decision deadlines, continuity-of-care protections, and enforcement penalties. It directly affects health carriers, PBMs, utilization review entities, enrollees, and prescribing providers, and it requires the Insurance Commissioner to collect and publish formulary information while authorizing the Attorney General to penalize PBM violations. The bill also expressly extends its framework to the Oklahoma Medicaid State Plan to the extent permitted by law.
The bill’s reception was broadly positive and largely noncontroversial in recorded votes. It cleared House and Senate committees overwhelmingly, passed the House and Senate with strong majorities, and ultimately received final passage without recorded opposition in the Senate fourth reading. The vote pattern indicates substantial support for reforms aimed at transparency, faster decisions, and continuity of prescription drug coverage.
No committee transcript excerpts were provided, so specific arguments are not documented here. Based on the bill’s provisions, likely areas of debate include whether the mandated timelines and deemed-authorization rule unduly constrain utilization review, whether the three-year prior authorization period for chronic conditions is too long, and whether the exceptions for opioids, controlled substances, and weight-loss drugs are appropriately drawn. Insurers and PBMs would be the most likely parties to raise implementation and cost concerns, while patients, providers, and advocates for chronic-condition management would likely support the access and continuity protections.